Experimental antiviral drug molnupiravir being developed by New Jersey drug manufacturer Merck with Ridgeback Bio shows a quick reduction of the infectious virus in a study among participants with early COVID-19.Molnupiravir…
N.J. drugmaker Merck reports new antiviral COVID drug quickly reduces virus
Updated Mar 06, 2021;
Posted Mar 06, 2021
Clinical trials of a new antiviral COVID treatment were said to be promising, Merck announced on Saturday.AP Photo/Matt Rourke, file
Facebook Share
New Jersey-based Merck said Saturday that the experimental antiviral drug molnupiravir it has been developing with Ridgeback Bio showed a quick reduction of the infectious virus in a study among participants with early COVID-19.
“We continue to make progress in our Phase 2/3 clinical programs evaluating molnupiravir in both outpatient and hospital settings,” said Roy Baynes, head of global clinical development and chief medical officer at Merck Research Laboratories.